QuidelOrtho Corporation

NASDAQ:QDEL

Medical - Instruments & Supplies

Healthcare
$9.57 +0.72%

+$0.09 today

Market cap
$656.62M
Beta
0.76
P/E (TTM)
-0.7
EPS (TTM)
-$17.76
52W Low $9.92High $35.58

Volume 2.13M

Average 2.35M

QDEL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

QuidelOrtho CorporationNASDAQ: QDEL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $44.9M fell 15.6% year over year, ahead of the -16.4% change in trailing-twelve-month research & development. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Research & development amounted to 6.8% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -15.6% holds above the trailing-twelve-month pace of -16.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$44.9M-2.0% QoQ
Last fiscal yearDec 2025
$186.2M-14.9% YoY
LTMMar 2026
$177.9M-16.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.6%——
1 year-14.9%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
186.2M USD
Year-over-year change
-14.9%
4-year CAGR
+18.1%

Research & Development vs competitors

How QDEL compares with its peers on the latest reported figures

  • QDEL's LTM Mar 2026 research & development of $177.9M is the 4th highest of the 9 companies compared; the peer median is $84.31M.
  • Its year-over-year change of -16.4% is the 6th highest of 8, against a peer median of -0.7%.
  • Research & development amounts to 6.7% of revenue for QDEL, versus a peer median of 7.8%.
QDEL Competitors Peer median
Research & Development for QDEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$1.41B -0.7%-1.7%3.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
RVTYRevvity, Inc.LTM Jul 2026$215.83M +5.2%-0.9%7.4%
QDELQuidelOrtho CorporationLTM Mar 2026$177.9M -16.4%-0.3%6.7%
OPKOPKO Health, Inc.LTM Mar 2026$122.39M +7.2%+18.8%21.1%
OSUROraSure Technologies, Inc.LTM Mar 2026$46.23M +68.7%+5.5%40.9%
TRIBTrinity Biotech plcLTM Dec 2025$3.63M -20.0%-4.3%8.3%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$227.19K -50.0%+4.3%2.3%
DGXQuest Diagnostics IncorporatedLTM Sep 2026$0 ——0.0%
Peer median (excluding QDEL) $84.31M-0.7%+0.0%7.8%

Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.7B3.27B3B2.78B2.73B
Cost of Revenue420.3M1.33B1.5B1.5B1.46B
Gross Profit1.28B1.94B1.5B1.29B1.27B
Gross Margin75.3%59.3%49.9%46.2%46.7%
Research & Development95.7M187.9M246.8M218.7M186.2M
Selling, General & Admin239.6M621M763.2M766.8M746.3M
Operating Expenses372.3M1.09B1.36B3.25B2.19B
Depreciation & Amortization52.7M283.6M457.2M453.4M442M
EBITDA953.3M1.09B607M(1.49B)(488.1M)
EBITDA Margin56.1%33.5%20.2%-53.5%-17.9%
Operating Income906M843.7M139.1M(1.96B)(919.2M)
Operating Margin53.3%25.8%4.6%-70.5%-33.7%
Interest Income300K1.3M2.2M00
Interest Expense700K74.5M178.9M188.3M177.6M
Other Income / Expenses(5.7M)(107.8M)(168.2M)(170.6M)(188.5M)
Income Before Tax900.3M735.9M(29.1M)(2.13B)(1.11B)
Pre-Tax Margin53.0%22.5%-1.0%-76.6%-40.6%
Income Tax Expense196.1M187.2M(19M)(79.5M)24.1M
Net Income704.2M548.7M(10.1M)(2.05B)(1.13B)
Net Margin41.5%16.8%-0.3%-73.7%-41.5%
EPS (Basic)16.749.66(0.15)(30.54)(16.69)
EPS (Diluted)16.439.56(0.15)(30.54)(16.69)
Weighted Avg Shares42.08M56.8M66.8M67.2M67.8M
Weighted Avg Shares (Diluted)42.87M57.4M66.8M67.2M67.8M

QuidelOrtho Corporation

NASDAQ:QDEL

Intrinsic Alpha fair value

Locked

Current Price

$9.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.